$Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials$

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials

AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan treatment for patients with HFpEF.Methods and resu...

Full description

Bibliographic Details
Main Authors:	Wanqian Yu, Hongzhou Zhang, Wen Shen, Fan Luo, Shuai Yang, Lujin Gan, Yuanbin Zhao, Pingping Yang, Qinghua Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	sacubitril/valsartan LCZ696 heart failure heart failure with preserved ejection fraction (HFpEF) meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.897423/full

Similar Items

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
by: Po‐Cheng Chang, et al.
Published: (2020-10-01)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
by: Yandrapalli S, et al.
Published: (2017-10-01)

The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
by: Giuseppe Dattilo, et al.
Published: (2023-09-01)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
by: Christof Burgdorf, et al.
Published: (2021-10-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 1 Review of Experience and Evidence in PARAGON-HF with Commentary
by: Soneil Guptha; Eteri Tsetskhladze
Published: (2023-07-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction
by: Gabrielle Fusco‐Allison, et al.
Published: (2021-10-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction—Out with the old and out with the new?
by: Luis Tolento Cortes, et al.
Published: (2022-07-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Does sacubitril/valsartan work in children with heart failure?—a pilot study
by: Yahe Xu, et al.
Published: (2023-11-01)

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
by: Antje Schauer, et al.
Published: (2021-03-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01)

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
by: Hongzhou Zhang, et al.
Published: (2020-12-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry
by: Matteo Pagnesi, et al.
Published: (2024-02-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction
by: Hao Chen, et al.
Published: (2022-10-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Editorial: Diabetes and heart failure: basic, translational, and clinical research
by: Laurent Metzinger, et al.
Published: (2023-05-01)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
by: Alaa Roushdy, et al.
Published: (2017-07-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility
by: Michael Chhor, et al.
Published: (2023-02-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
by: Rahul N. Patel, et al.
Published: (2023-12-01)

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
by: Adrian V. Hernandez, et al.
Published: (2023-05-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose
by: Janet D. Pierce, et al.
Published: (2018-04-01)

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
by: Fabiana Lucà, et al.
Published: (2024-02-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
by: Mariëlle Scheffer, et al.
Published: (2020-12-01)

Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study
by: Xiao-mei Huang, et al.
Published: (2024-01-01)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
by: Clement Lau, et al.
Published: (2022-07-01)